Research Overview
Thymalin is a low molecular weight thymic peptide preparation whose primary active fragment is the Glu-Trp dipeptide, supplied here as a 10mg lyophilised vial. It carries a molecular weight of 333.34 g/mol and is supplied with documented analytical verification by HPLC and mass spectrometry.
The compound has been investigated in Russian and Eastern European research literature since the 1970s and 1980s, with subsequent publications in international gerontology and immunology journals. Research has focused on thymic signalling, immune-cell activity, lymphocyte regulation and cellular-response models associated with ageing biology.
Origin Research supplies Thymalin as a sterile lyophilised powder for laboratory research applications only. The material is sealed under inert atmosphere, shipped under temperature-conscious conditions and supported by batch documentation available upon request. It is not intended for human consumption or veterinary use.
Mechanism Studied in Research
Thymalin has been studied in receptor-binding and gene-expression research as a short bioregulatory peptide that has been investigated in nuclear transcription models. Published research has characterised the Glu-Trp dipeptide in studies of chromatin interaction, DNA accessibility and immune-cell signalling.
Research literature has examined effects on T-cell differentiation pathways, cytokine transcription, lymphocyte proliferation and macrophage activity. Additional investigations have explored thymic peptide signalling in ageing-related immune models and cellular-response research.
The peptide has also been investigated in oxidative-stress models, inflammatory signalling research and immune-regulation pathways. These studies position Thymalin as a laboratory research compound for examining thymic peptide effects on cellular signalling and immune-system models.
Research Applications
Thymalin has been investigated across several laboratory research domains, especially gerontology, immune regulation and peptide bioregulation research.
In gerontology and longevity research, the peptide has been studied in ageing-related models where investigators examine immune-cell activity, oxidative stress markers and cellular-response patterns.
In immunology research, Thymalin has been investigated for its effects on lymphocyte activity, cytokine production, T-cell regulation and macrophage response models.
Additional applications include chromatin-accessibility studies, peptide-signalling research and comparative thymic peptide investigations alongside compounds such as Thymosin Alpha-1. All applications are restricted to laboratory research use only.
Reconstitution Reference
Thymalin is supplied as a sterile lyophilised powder in a 10mg vial. For laboratory reconstitution, researchers commonly use bacteriostatic water or sterile laboratory-grade diluents.
A common working example is the addition of 2ml of bacteriostatic water to the vial, producing a concentration of 5mg/ml. The diluent should be introduced slowly down the inner wall of the vial without directing the stream directly onto the lyophilised cake.
The vial should be allowed to dissolve passively, with gentle swirling if required. Vigorous shaking is not recommended. The resulting solution should appear clear and free of visible particulate before use in laboratory protocols.
Storage and Handling
Lyophilised Thymalin should be stored at -20°C in a sealed, light-protected container with low humidity. Under these conditions, long-term stability is maintained according to batch documentation.
Short-term storage at 2°C to 8°C is acceptable before reconstitution. Once reconstituted, working solutions should be refrigerated and used within laboratory-established timelines.
Repeated freeze-thaw cycles should be avoided. Vials should be returned to controlled storage promptly after use, and reconstitution date, diluent volume and final concentration should be documented for traceability.
References
[2] Anisimov V.N., Khavinson V.K., Morozov V.G. (2003). Twenty years of study on effects of pineal peptide preparations in experimental gerontology and oncology. Annals of the New York Academy of Sciences. PMID 11762148
[3] Khavinson V.K. (2004). Peptide bioregulation of aging: results and prospects. Biogerontology. PMID 15039940
[4] Morozov V.G., Khavinson V.K. (1997). Natural and synthetic thymic peptides as therapeutics for immune dysfunction. International Journal of Immunopharmacology.